Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Developmental Cell
|
July 15, 2010
MADD-2, a homolog of the Opitz syndrome protein MID1, regulates guidance to the midline through UNC-40 in Caenorhabditis elegans
Mariam Alexander, Guillermo Selman, Ashwin Seetharaman, et al.
Immunology
|
October 23, 2022
mTORC2 contributes to systemic autoimmunity
Xian Zhou, Haiyu Qi, Meilu Li, et al.
JAMA Oncology
|
May 7, 2026
Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults
Adam H Fox, Ralph C Ward, Mariam Alexander, et al.
Cytojournal
|
December 29, 2025
Prominent repair-like changes that mimic atypical squamous cells after radiation treatment in the lung: A report of two cases
Benjamin L Petrykowski, Raul Virginio Rodriguez, Reginald Munden, et al.
Rheumatology (Oxford, England)
|
December 10, 2024
Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in systemic lupus erythematosus
Minji Ai, Xian Zhou, Michele Carrer, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2024
Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus
Minji Ai, Xian Zhou, Michele Carrer, et al.
Development (Cambridge, England)
|
February 13, 2009
An UNC-40 pathway directs postsynaptic membrane extension in Caenorhabditis elegans
Mariam Alexander, Kevin Ka Ming Chan, Alexandra B Byrne, et al.
Journal of Onco-Nephrology
|
February 18, 2026
Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States
Samhita Boppana, Christopher D Blosser, Allison B Webber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Developmental Cell
|
July 15, 2010
MADD-2, a homolog of the Opitz syndrome protein MID1, regulates guidance to the midline through UNC-40 in Caenorhabditis elegans
Mariam Alexander, Guillermo Selman, Ashwin Seetharaman, et al.
Immunology
|
October 23, 2022
mTORC2 contributes to systemic autoimmunity
Xian Zhou, Haiyu Qi, Meilu Li, et al.
JAMA Oncology
|
May 7, 2026
Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults
Adam H Fox, Ralph C Ward, Mariam Alexander, et al.
Cytojournal
|
December 29, 2025
Prominent repair-like changes that mimic atypical squamous cells after radiation treatment in the lung: A report of two cases
Benjamin L Petrykowski, Raul Virginio Rodriguez, Reginald Munden, et al.
Rheumatology (Oxford, England)
|
December 10, 2024
Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in systemic lupus erythematosus
Minji Ai, Xian Zhou, Michele Carrer, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2024
Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus
Minji Ai, Xian Zhou, Michele Carrer, et al.
Development (Cambridge, England)
|
February 13, 2009
An UNC-40 pathway directs postsynaptic membrane extension in Caenorhabditis elegans
Mariam Alexander, Kevin Ka Ming Chan, Alexandra B Byrne, et al.
Journal of Onco-Nephrology
|
February 18, 2026
Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States
Samhita Boppana, Christopher D Blosser, Allison B Webber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.
Page
of 2